The announcement came with the kind of confidence that venture-backed health tech founders have learned to project: €5 million in seed funding, a partnership with Sanofi, and an audacious goal to become France's first reimbursed digital therapy for insulin pen users. DiappyMed, a medtech company tucked away in Montpellier, made its pitch in late March. Whether the regulatory and reimbursement systems will cooperate remains an open question.
The funding round—led by Ventech and its impact vehicle AFI Ventures, with backing from SOFILARO/CALEN and IRDI Capital Investissement—is substantial for a seed stage. By the standards of French medtech, it's among the largest in recent memory for companies at this stage. Yet the real story isn't the capital. It's what DiappyMed is trying to do with it: crack a market that has proven stubbornly resistant to digital therapeutics, particularly when reimbursement is the endgame.
The company's product, EkiYou, is an AI-powered insulin dosing assistant. Think of it as a very sophisticated calculator for people with diabetes who inject insulin multiple times daily. Approved as a Class IIb medical device under European regulations, the app pulls together real-time blood sugar readings, carbohydrate intake (drawn from a database of over 400,000 foods), and personalized correction factors to recommend how much rapid-acting insulin a patient should take. It can link to continuous glucose monitors and requires a prescription in France—a regulatory detail that matters more than it might seem at first glance.
The Promise of Precision, One Meal at a Time
For anyone unfamiliar with the daily arithmetic of diabetes management, insulin dosing is relentless. Get it wrong and blood sugar swings dangerously high or low. Get it right and… well, you do it all again at the next meal. DiappyMed's founders—CEO Coralie Lefevre, Chief Medical & Scientific Officer Omar Diouri, and CTO Youssef Raqui—launched the company in early 2021 with the thesis that machine learning could take some of that burden off patients' shoulders.
The clinical data they've assembled is respectable, if not yet definitive. According to results presented in abstract form, EkiYou showed a 5.75% improvement in post-meal time-in-target glucose range and a 24% reduction in corrective insulin doses. The company developed those findings in partnership with a community of more than 2,000 patients and diabetologists through trials including GLUCAL and GLUCAL3.
Now they're running a larger multicenter randomized controlled trial for EkiYou V2, which they unveiled at the French Diabetes Society congress in March. This version introduces something the company describes as novel: weekly algorithmic adjustments for basal insulin dose, carbohydrate ratios, and correction factors. Whether it's truly first-of-its-kind for pen users, as DiappyMed claims, is harder to verify independently. Competitors aren't sitting still.
The trial, registered as NCT06738849, expects to complete enrollment by late May 2026 and report final results by the end of November 2026. Those timelines will matter—a lot—if DiappyMed is serious about securing reimbursement this year.
A Crowded Field, A Narrow Bet
DiappyMed isn't operating in a vacuum. The insulin dosing space already includes mySugr's Bolus Calculator (backed by Roche), Insulia from Aptar Digital Health, and DreaMed Advisor Pro, all holding CE marks and in some cases FDA clearance. Some of these competitors have deeper pockets and broader distribution networks.
What DiappyMed has instead is focus. The company is deliberately targeting insulin pen users in France—a population that hasn't received the same level of digital innovation as those using insulin pumps or automated closed-loop systems. It's a strategic choice, born partly from necessity and partly from insight. Pen users represent a massive but underserved segment, and France's relatively structured reimbursement environment offers a clearer path (if not an easy one) than the fragmented U.S. market.
The Sanofi partnership, announced alongside the funding, extends an earlier collaboration. Sanofi hosted DiappyMed at the SFD 2024 diabetes congress and worked with the startup on EkiYou Carbs, a nutrition companion app launched in late 2022. More recently, DiappyMed inked deals with myDiabby Healthcare, a reimbursed telemonitoring platform, and ISIS DIABÈTE, a home-care provider. These partnerships suggest an ecosystem strategy: embedding EkiYou within a broader care infrastructure rather than trying to go it alone.
The Reimbursement Riddle
Here's where things get interesting—and uncertain. DiappyMed has set its sights on becoming the first reimbursed digital therapy in France for insulin pen users, though as of early April that reimbursement hasn't been confirmed. French health authorities aren't known for moving quickly, and digital therapeutics occupy an awkward category between traditional pharmaceuticals and medical devices.
If the company succeeds, it would validate not just EkiYou but a broader playbook for digital health in Europe. Industry observers note that reimbursement transforms a product from a nice-to-have into standard care. It also generates revenue at scale in a way that direct-to-consumer models rarely achieve in highly regulated health systems.
The stakes extend beyond DiappyMed. Nearly 589 million adults worldwide were living with diabetes as of recent estimates, with related health spending topping $1 trillion globally. France ranks among the top ten countries for diabetes expenditure, meaning cost containment is a national priority. A digital tool that demonstrably improves outcomes while reducing waste (those 24% fewer correction boluses, for instance) could appeal to budget-conscious health systems. Or it could get lost in bureaucratic limbo. Perhaps both.
What Happens Next
The €5 million will fund team expansion, particularly for training healthcare professionals and supporting patients—roles that matter when adoption depends on physician prescription. DiappyMed, which listed 11-50 employees on its LinkedIn profile as of April 2026, previously raised €1.2 million in late 2023 from business angels, Bpifrance, and IRDI, following a crowd-equity campaign earlier that year. The company is ISO 13485 certified and incubated at BIC Montpellier/MedVallée, part of the region's modest but growing health tech cluster.
Lefevre and her co-founders are betting that the combination of clinical evidence, strategic partnerships, and regulatory savvy will be enough. They're also betting that France's system, for all its complexity, rewards companies that play by its rules. The trial results later this year will tell us whether the algorithm works as promised. The reimbursement decision—whenever it comes—will tell us whether the French health system is ready for what DiappyMed is selling.
For now, the company has capital, momentum, and a clear target. Whether that's enough to navigate the labyrinth between regulatory approval and widespread adoption is another matter entirely.
